Stock listing

Dusseldorf:2VSA Verastem, Inc. Aktie

German listing (Dusseldorf) of Verastem, Inc. · home listing NASDAQ:VSTM

Follow Verastem, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:VSTM

$8.65 USD -0.58 (-6.3%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:VSTM

Verastem, Inc. logo
Ticker
Dusseldorf:2VSA
Asset type
Stock
Exchange
Dusseldorf
Currency
EUR

What changed lately

Calls

Replays

  • Verastem (NASDAQ:VSTM) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Verastem (NASDAQ:VSTM) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 4:30 PM ET

    Watch Transcript

  • Verastem (NASDAQ:VSTM) Q4 2025 Earnings Call

    Wed, Mar 04, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Oct 14, 2026

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

Oct 14, 2026

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

Oct 14, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 5, 2026

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

Oct 2, 2026

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

Sep 28, 2026

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

Sep 24, 2026

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Sep 8, 2026

Verastem Oncology to Participate in Upcoming September Investor Conferences

Sep 2, 2026

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Aug 6, 2026

All Verastem, Inc. news

Financings

  • Public offering of common stock and pre-funded warrants

    Oct 14, 2026

    Announced: about US$250M · US$8 a share · Jefferies +3

    Dealers: Jefferies (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), B. Riley Securities

    Use of proceeds: Clinical development of product candidates including the VS-7375 program, working capital and general corporate purposes

    Announced Oct 14, 2026

Read by 6ix AI from the company's releases

Decks

Verastem, Inc. on 6ix

News releases
42 in the last 12 months · 184 in all · newest Oct 14, 2026 · oldest 2019
Calls
5 calls with a replay · 5 with a transcript · latest Aug 6, 2026
Decks
46 decks · latest Oct 14, 2026

Where Verastem, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VSTM · Home listingNASDAQUnited StatesUSD
LS Exchange:A3EHM3LS ExchangeGermanyEUR
Lang & Schwarz:A3EHM3Lang & SchwarzGermanyEUR
gettex:2VSAgettexGermanyEUR
BOATS:VSTMBOATSUnited StatesUSD
LSE:0LOVLSEUnited KingdomUSD
Dusseldorf:2VSA · This pageDusseldorfGermanyEUR
Frankfurt:2VSAFrankfurtGermanyEUR
Hamburg:2VSAHamburgGermanyEUR
Munich:2VSAMunichGermanyEUR
Stuttgart:2VSAStuttgartGermanyEUR
Tradegate:2VSATradegateGermanyEUR

Log in to ask 6ix AI your own questions about Verastem, Inc.